{"id":"NCT00577473","sponsor":"Warner Chilcott","briefTitle":"Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)","officialTitle":"A Double-blind, Randomized, 6 Week, Parallel-group Design Clinical Trial in Patients With Mildly to Moderately Active Ulcerative Colitis to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-02","primaryCompletion":"2003-02","completion":"2003-02","firstPosted":"2007-12-20","resultsPosted":"2011-06-22","lastUpdate":"2011-09-16"},"enrollment":301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"mesalamine","otherNames":[]},{"type":"DRUG","name":"mesalamine","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) versus Asacol 2.4 g/day (400 mg tablet","primaryOutcome":{"measure":"Percentage of Patients Classified as Treatment Success at Week 6, ITT Population","timeFrame":"6 weeks","effectByArm":[{"arm":"Asacol 2.4 g/Day","deltaMin":51.3,"sd":null},{"arm":"Asacol 4.8 g/Day","deltaMin":55.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4411"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":["21385195","21255059"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":154},"commonTop":["Headache","Nausea","Abdominal Pain","Infection","Diarrhea"]}}